First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer

Conditions: Advanced Cancer; Breast Cancer
Interventions: Drug: OKI-219; Drug: Fulvestrant; Drug: Trastuzumab
Sponsors: OnKure, Inc.
**RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 13, 2024Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments